Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq traded relatively flat for the week, continuing to consolidate year-to-date gains narrowly above 21-DMA (4,077/11,684) support. We will shift the market status to Uptrend Under Pressure should both indices close below this moving average. Support below this level for the S&P 500 is the 50-DMA (3,978), while the Nasdaq’s next level is the 200-DMA (11,422). Distribution increased to five and three, respectively, with one day expiring on each index next week.

O’Neil Health Care Weekly

XLV declined for a seventh straight week, despite losses of only 15bps. The difference this week was that its relative
strength (RS) line versus both the S&P 500 and Nasdaq ticked higher as it comes into absolute support at its 200-DMA
($130.57). This warrants a move from under to equal weight as the sector is due to bounce from oversold
conditions.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq pulled back towards 21-DMA (4,054/11,548) support this week, consolidating sharp year-to-date gains. Should this level break, the next level for the S&P 500 is the 50-DMA (3,969), while the Nasdaq’s next level is the 200-DMA (11,438). Distribution remains relatively low at three and two, respectively, with no expiration next week.

O’Neil Health Care Weekly

XLV declined for a sixth straight week, despite losses of only 11bps. The sector continues to heavily underperform the
broader market, with its relative strength (RS) line versus both the S&P 500 and Nasdaq hitting another low. Stay
underweight the sector and remain patient. On an absolute basis, XLV is nearing 200-DMA ($130.67) support.

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq rallied strongly for a second straight week, clearing above 4,100 and 200-DMA resistance, respectively. Near-term support is now the sharply rising 10-DMA (S&P 500: 4,076; Nasdaq: 11,645). The distribution day count stands at four and two, respectively, with two days expiring on the S&P 500 and one on the Nasdaq next week.

O’Neil Health Care Weekly

XLV declined 78bps last week, its fifth straight down week. Its relative strength line (versus the S&P 500 and Nasdaq)
continues to sharply decline, warranting an equal to underweight sector positioning which we have now been
recommending for the past three weeks. On an absolute basis, support remains the 200-DMA ($130.80).

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq rallied strongly this week, with both now trading above all key moving averages including the 200-DMA (S&P 500: 3,958; Nasdaq: 11,507). This level will now act as initial near-term support until other shorter-term moving averages rise above. The next level of resistance on the S&P 500 is 4,100 to 4,119, while the Nasdaq’s next test is its September high of 12,270. The distribution day count remains at three and two, respectively.

O’Neil Health Care Weekly

XLV fell 1.1% last week, continuing to underperform the broader market and leading to another low in its Relative Strength
line. This lag continues to warrant an equal to underweight sector positioning. On an absolute basis, support is now at
the 200-DMA ($130.97).

Market View

The U.S. market remains in a Confirmed Uptrend. The S&P 500 and Nasdaq shook out below their respective 50-DMA (S&P 500: 3,929; Nasdaq: 10,908) Thursday, before strongly regaining that level Friday. The S&P 500 now faces a range of resistance between 4,015 to 4,100, while the Nasdaq has resistance from ~11,492 to its rolling 200-DMA (11,567). The distribution day count stands at three and two, respectively.

O’Neil Health Care Weekly

XLV traded relatively flat for a 4th straight week, falling 16bps and again underperforming the broader market. Its RS line continues to fall, warranting an equal to underweight sector positioning. On an absolute basis, there is support at ~$133 to $134, before the 200-DMA.